Key takeaways
- FDA’s Pharmacy Compounding Advisory Committee met on 23–24 July 2026 to advise on seven peptides for the 503A bulks list.
- FDA staff proposed that none be included; the committee voted in favour of six and against emideltide (DSIP).
- HHS confirms the six favourable votes in its October 2026 policy; the vote counts are still press-reported because FDA has not posted minutes.
- An advisory vote is not an approval and does not change the bulks list; only rulemaking does, and none has been proposed.
- The vote’s practical effect came through HHS’s 28 October enforcement-discretion policy for the same six.
01The meeting and the seven peptides
FDA announced the meeting in the Federal Register on 16 April 2026 (91 FR 20465, Docket FDA-2025-N-6895). The Pharmacy Compounding Advisory Committee met at FDA’s White Oak campus in Silver Spring, Maryland, on 23 and 24 July 2026, and the docket closed to comments on 22 July. Its task was to advise FDA on whether each substance should go on the 503A bulks list: the list of ingredients that state-licensed pharmacies may use in compounding when no monograph or approved drug covers them.
FDA’s briefing document proposed, for every form of every substance, that it “NOT be included” on the list. FDA reviewed each one for the specific uses its nominators proposed; those uses are set out in FDA’s briefing documents, linked from the meeting page.
| Substance (forms voted) | Day | FDA proposal | Committee outcome | Reported vote (for–against–abstain) |
|---|---|---|---|---|
| BPC-157 (free base, acetate) | 23 Jul | Do not include | In favour | 8–6–1 |
| KPV (free base, acetate) | 23 Jul | Do not include | In favour | 8–6–1 |
| TB-500 (free base, acetate) | 23 Jul | Do not include | In favour | 8–6–1 |
| MOTS-c (free base, acetate) | 23 Jul | Do not include | In favour | 7–5–2 |
| Emideltide, also called DSIP (free base, acetate) | 24 Jul | Do not include | Against | 6–7–1 |
| Epitalon (free base, acetate) | 24 Jul | Do not include | In favour | 7–4–1 |
| Semax (free base, acetate) | 24 Jul | Do not include | In favour | 8–5–1 |
Committee outcomes for the six substances voted through are confirmed in HHS’s October 2026 policy (Appendix B). Vote counts and the emideltide outcome are press-reported; see “The official record” below.
02The questions
FDA put 14 voting questions to the committee: for each of the seven substances, one on the free base and one on the acetate salt. Each was worded the same way: “Should [substance] be placed on the list?”
The press reports we rely on give one count per substance rather than separate counts per form. Whether any substance’s free base and acetate votes differed will only be settled by FDA’s minutes.
03The official record, and what is still pending
As of 17 November 2026, FDA’s meeting page (content current as of 6 August 2026) carries the briefing documents, the questions, the agenda, the roster and FDA’s slide presentations. It does not carry minutes or a transcript.
- Confirmed by a government document: the committee voted in favour of BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax, and FDA’s drug centre (CDER) recommended against listing each of them. HHS records both facts, substance by substance, in Appendix B of its October 2026 policy.
- Reported, not yet confirmed by FDA: the vote counts, and the committee’s rejection of emideltide. For 23 July, The Washington Post reported the counts for and against; the abstentions, and all 24 July counts, are from the American Med Spa Association’s same-day report. FDA’s public webcast of the meeting is linked from its meeting page.
04What an advisory vote does, and does not do
FDA describes advisory committees this way: they “make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.” For the 503A list, the statute requires FDA to consult this committee before it issues the regulation that creates the list (21 U.S.C. 353a(c)(1)). A substance gets on the list only through that rulemaking, which is codified at 21 CFR 216.23(a).
- The vote did not approve any peptide as a medicine.
- It did not add anything to the 503A bulks list. As of 17 Nov 2026, no proposed rule has appeared in the Federal Register.
- It is not an FDA finding that any substance is safe or effective. FDA’s own staff had proposed rejecting all seven.
- It did not change anti-doping rules, or the status of products sold as research chemicals.
05What happened next
The vote’s practical effect came through HHS, not FDA. On 28 October 2026 HHS filed an interim enforcement-discretion policy covering exactly the six substances the committee backed. It was published in the Federal Register on 30 October (91 FR 68526). HHS cites “the recommendations of a recent Pharmacy Compounding Advisory Committee” as part of its basis. Until each peptide is addressed in a final rule, HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding the six under ten conditions. Emideltide is not covered. Full detail: the HHS policy explained.
The vote did not settle the scientific disagreement. FDA staff set out their objections in the briefing documents; HHS’s policy appendix answers them substance by substance, citing new characterisation data such as endotoxin and impurity results. The Washington Post reported that the committee is scheduled to review five more peptides before the end of February 2027. FDA had not published a meeting notice in the Federal Register when we checked.
06What we don’t know
The official counts. Per substance and per form, until FDA posts minutes.
Whether FDA will propose listing any of the six, and on what evidence. FDA’s staff recommendation was against all of them.
Whether the next meeting goes ahead on schedule. No notice yet.
For what the vote means for each market, see peptides and US law and is BPC-157 legal?
This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.